Dynavax to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024

Rhea-AI Summary

Dynavax Technologies (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on vaccine development, has announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day. Interested parties can access the webcast through the company's investor relations website, with a replay available for 30 days. Participants are advised to register and connect 10 minutes before the call.

News Market Reaction – DVAX

-0.56%

1 alert

-0.56% News Effect

On the day this news was published, DVAX declined 0.56%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

EMERYVILLE, Calif., Oct. 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter 2024 financial results on Thursday, November 7, 2024, after the U.S. financial markets close.

Dynavax will host a conference call and live audio webcast on Thursday, November 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT.

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations. A replay of the webcast will be available for 30 days following the live event.

To dial into the call, participants will need to register for the call using the caller registration link. It is recommended that participants dial into the conference call or log into the webcast approximately 10 minutes prior to the call.

About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant with adjuvanted vaccine clinical programs for shingles and Tdap, and through global collaborations, currently focused on adjuvanted vaccines for COVID-19, plague, seasonal influenza and universal influenza. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn and Twitter.

For Investors/Media:
Paul Cox
pcox@dynavax.com
510-665-0499 

Nicole Arndt
narndt@dynavax.com
510-665-7264

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-report-third-quarter-2024-financial-results-and-host-conference-call-on-november-7-2024-302286555.html

SOURCE Dynavax Technologies

FAQ

When will Dynavax (DVAX) report Q3 2024 earnings?

Dynavax will report its third quarter 2024 financial results on Thursday, November 7, 2024, after the U.S. financial markets close.

What time is Dynavax's (DVAX) Q3 2024 earnings call?

Dynavax will host its Q3 2024 earnings conference call and webcast on Thursday, November 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT.

How can I access Dynavax's (DVAX) Q3 2024 earnings webcast?

The earnings webcast can be accessed through the 'Events & Presentations' page in the 'Investors' section of Dynavax's website at investors.dynavax.com/events-presentations.